In recent years, scientific research has increasingly focused on the cardiovascular benefits of omega-3 polyunsaturated fatty acids (n-3 PUFAs) supplements. The most promising results emerged from the new trials on a high-dose eicosapentaenoic acid (EPA)-only approach, instead of the previously prescribed therapy with EPA + docosahexaenoic acid (DHA). The evidence of the reduction of cardiovascular events in patients at high cardiovascular risk with EPA is intriguing. However, physicians have expressed concern about the potential high risk of atrial fibrillation (AF) occurrence due to such an approach. This study aims to investigate the current evidence on the cardiovascular benefits of EPA and its association with atrial arrhythmogenesis. Current guidelines consider EPA (as IPE) treatment for selected patients but with no specific indication regarding AF risk evaluation. We propose a flowchart that could be a starting point for the future development of an algorithm to help clinicians to prescribe EPA safely and effectively, especially in patients at high risk of incipient AF.

Eicosapentaenoic Acid: between Cardiovascular Benefits and the Risk of Atrial Fibrillation / F. Egalini, M. Rossi, M. Massussi, G. Gaggero, G. Beccuti, A. Benso, M.F. Piepoli, F. Broglio. - In: ENDOCRINE, METABOLIC & IMMUNE DISORDERS DRUG TARGETS. - ISSN 1871-5303. - 24:6(2024), pp. 651-663. [10.2174/0118715303280825231122153024]

Eicosapentaenoic Acid: between Cardiovascular Benefits and the Risk of Atrial Fibrillation

M.F. Piepoli;
2024

Abstract

In recent years, scientific research has increasingly focused on the cardiovascular benefits of omega-3 polyunsaturated fatty acids (n-3 PUFAs) supplements. The most promising results emerged from the new trials on a high-dose eicosapentaenoic acid (EPA)-only approach, instead of the previously prescribed therapy with EPA + docosahexaenoic acid (DHA). The evidence of the reduction of cardiovascular events in patients at high cardiovascular risk with EPA is intriguing. However, physicians have expressed concern about the potential high risk of atrial fibrillation (AF) occurrence due to such an approach. This study aims to investigate the current evidence on the cardiovascular benefits of EPA and its association with atrial arrhythmogenesis. Current guidelines consider EPA (as IPE) treatment for selected patients but with no specific indication regarding AF risk evaluation. We propose a flowchart that could be a starting point for the future development of an algorithm to help clinicians to prescribe EPA safely and effectively, especially in patients at high risk of incipient AF.
atrial fibrillation; cardiovascular events; eicosapentaenoic acid; omega-3; n-3 PUFA; EPA
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
Settore MEDS-07/B - Malattie dell'apparato cardiovascolare
2024
11-dic-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
Egalini_Endocrine.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 3.23 MB
Formato Adobe PDF
3.23 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1079428
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact